Targeted treatments might be especially beneficial for patients with advanced cancers, as HERV-K (HML-2) Gag antibodies are predictors of poor prognosis and correlate with prostate cancer progression [238,243,279]. This evidence concerns the gene CLEC10A and prostate cancer.